Search results for "Neoplasms."

showing 10 items of 7882 documents

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

2018

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA…

neoplasmsdigestive system diseases
researchProduct

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

2016

Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-generation hypomethylating agent, which inhibits DNA methyltransferases. Guadecitabine is formulated as a dinucleotide of decitabine and deoxyguanosine that is resistant to cytidine deaminase (CDA) degradation and results in prolonged in vivo exposure to decitabine following small volume subcutaneous administration of guadecitabine. Here we found that guadecitabine is an effe…

neoplasmsdigestive system diseases
researchProduct

Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

2022

To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harboring EGFR mutations. A partitioned survival model was developed to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) from the perspective of the Spanish National Health System. Two Bayesian NMAs were performed independently, by using the polynomial fraction method to fit Kaplan–Meier curves for overall survival and progression-free survival. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty. The ICER was calculated for the f…

neoplasmsrespiratory tract diseases
researchProduct

Neuroendocrine Tumors: A Comprehensive Review on Nutritional Approaches.

2022

Simple Summary Neuroendocrine neoplasms and their main subtype neuroendocrine tumors have an increasing incidence worldwide, associated with a high survival and prevalence rate. Both the tumor itself and systemic therapy can have an impact on patients' nutrition. Conversely, preliminary data suggest that malnutrition has a negative impact on the development and prognosis of neuroendocrine tumors, as does obesity. The aim of this review is to condense the latest evidence on the role of the most widely used dietary patterns, the Mediterranean diet, the ketogenic diet and intermittent fasting, in the context of neuroendocrine tumors. Nutritional plans are an integral part of the multidisciplin…

neuroendocrine tumors.Cancer Researchneuroendocrine neoplasmsfastingneuroendocrine neoplasmOncologyketogenic dietMediterranean dietcancerneuroendocrine tumorsdietmediterranean diet; cancer; diet; fasting; ketogenic diet; neuroendocrine neoplasms; neuroendocrine tumorsCancers
researchProduct

The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model

2020

2-Methoxyestradiol is one of the natural 17&beta

neuronal nitric oxide synthaseProgrammed cell death2-methoxyestradiolLactams MacrocyclicAntineoplastic AgentsBone NeoplasmsModels BiologicalArticleCatalysisHsp90 inhibitorNitric oxidelcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundDownregulation and upregulationosteosarcomaHeat shock proteinBenzoquinonesAnimalsHumansDrug InteractionsHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsPhysical and Theoretical Chemistrygeldanamycinlcsh:QH301-705.5Molecular BiologySpectroscopyAntibiotics AntineoplasticbiologyOrganic ChemistryGeneral MedicineGeldanamycinHsp90Computer Science ApplicationsHsp70lcsh:Biology (General)lcsh:QD1-999chemistryCancer researchbiology.proteinInternational Journal of Molecular Sciences
researchProduct

Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weight or body surface area (BSA)-based approaches may fail to fully reflect the complexity of the anthropometric features besides obesity in cancer patients suffering from sarcopenia. Likewise, there is a lack of pharmacokinetic data on obese patients for the majority of chemotherapeutic agents as well as for new target drugs and immunotherapy. Therefore, although the available findings point to the …

obesityCancer Researchmedicine.medical_specialtypharmacokinetic parametersConsensusBSAcancer drug dosingPopulationchemotherapy doseAntineoplastic AgentsReviewOverweightNODosing schedulesNeoplasmsPhysiciansInternal medicineHumansMedicineDosingLS4_3educationBody surface areaeducation.field_of_studybusiness.industryCancerCytotoxic chemotherapymedicine.diseaseOncologyBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parametersPosition paperBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parameters; Consensus; Humans; Obesity; Antineoplastic Agents; Neoplasms; Physiciansmedicine.symptombusinessESMO Open
researchProduct

Effectiveness of peer support on health-related quality of life in recently diagnosed breast cancer patients : a randomized controlled trial

2019

Purpose: Breast cancer is the most common cancer of Finnish women. Peer support could be a way to help breast cancer patients to deal with the disease but studies on its effectiveness have produced conflicting results. The aim of this randomized controlled trial was to study the effectiveness of peer support on health-related quality of life (HRQoL) of breast cancer patients. Methods: Patients with recently diagnosed breast cancer at the Helsinki University Hospital were randomly allocated to intervention (n = 130) or control (n = 130) groups. The intervention group patients received peer support via telephone one to five times according to their preference. The control group received usual…

oma-apuryhmätvertaistukicontrol groupspotilaatrintasyöpärandomized controlled trialbreast neoplasmssosiaalinen tukikliiniset kokeetelämänlaatuRCT
researchProduct

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)

2020

ObjectiveTo investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking surgery in terms of perioperative complications and progression-free survival, in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high tumor load.MethodsPatients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (stage IIIC-IV) underwent laparoscopy. Patients with high tumor load assessed by a standardized laparoscopic predictive index were randomly assigned (1:1 ratio) to undergo either primary debulking surgery followed by adjuvant chemotherapy (arm A), or neoadjuvant chemotherapy followed by int…

operativemedicine.medical_specialtymedicine.medical_treatmentPopulationlaw.inventionperitoneal neoplasm03 medical and health sciences0302 clinical medicineRandomized controlled triallawperitoneal neoplasmspostoperative complicationsMedicineEpithelial ovarian cancerpostoperative complication030212 general & internal medicineStage (cooking)educationLaparoscopyChemotherapyeducation.field_of_studymedicine.diagnostic_testbusiness.industryObstetrics and GynecologyGeneral MedicinePerioperativeepithelial ovarian cancer.medicine.diseaseDebulkingsurgical proceduresSurgerysurgical procedureovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisbusinessOvarian cancerFallopian tube
researchProduct

Botulinum Toxin A for Oral Cavity Cancer Patients: In Microsurgical Patients BTX Injections in Major Salivary Glands Temporarily Reduce Salivary Prod…

2012

Abstract: In patients suffering from oral cavity cancer surgical treatment is complex because it is necessary to remove carcinoma and lymph node metastasis (through a radical unilateral or bilateral neck dissection) and to reconstruct the affected area by means of free flaps. The saliva stagnation in the post-operative period is a risk factor with regard to local complications. Minor complications related to saliva stagnation (such as tissue maceration and wound dehiscence) could become major complications compromising the surgery or the reconstructive outcome. In fact the formation of oro-cutaneous fistula may cause infection, failure of the free flap, or the patient’s death with carotid b…

oro-cutaneous fistulaMicrosurgerysaliva-related complicationsmedicine.medical_specialtySalivaHealth Toxicology and Mutagenesismedicine.medical_treatmentSettore MED/19 - Chirurgia Plasticalcsh:MedicineFree flapToxicologySalivary GlandsSurgical FlapsArticleforearm free flapPostoperative ComplicationsBotulinum toxinMajor Salivary GlandmedicineHumansBotulinum Toxins Type ARadionuclide ImagingSalivaBotulinum toxin; salivary production; oral cancer; free flap complications; saliva-related complications; forearm free flap; oro-cutaneous fistula; salivary major glandsfree flap complicationsMouth neoplasmWound dehiscencebusiness.industryBotulinum toxin salivary production oral cancer free flap complications saliva-related complications forearm free flap oro-cutaneous fistula salivary major glandslcsh:RNeck dissectionSialorrheaPlastic Surgery Proceduresoral cancerMicrosurgerymedicine.diseaseBotulinum toxinsalivary productionSurgeryTreatment Outcomesalivary major glandsMouth Neoplasmsbusinessmedicine.drugToxins
researchProduct

Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.

2021

Abstract Introduction Renal cell carcinoma (RCC) accounts for 2–3% of all tumors being the most frequent solid lesion in the kidney. Objective To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness. Patients and Methods Experimental analytical study with 57 patients who underwent radical and partial nephrectomy between 2005 and 2011, all with diagnosis of ccRCC and minimum post-operative follow-up of 36 months. The pathological study included IHC determination of biomarkers associated (CAIX, CAM 5.2, CD10, c-erbB-2, EGFR, HIF-1a, Ki67, MDM2, PAX-2 y 8, p53, survivin and VEGFR 1 and 2). …

p530301 basic medicineMaleCancer Researchmedicine.medical_treatmentGastroenterologyNephrectomy0302 clinical medicineFHITRenal cell carcinomaCDKN2ANeoplasm MetastasisClear cell renal carcinomaRC254-282KidneyBRCA1 y 2Neoplasms. Tumors. Oncology. Including cancer and carcinogensCDKN2A: cyclin-dependent kinase Inhibitor 2AMiddle AgedPrognosisImmunohistochemistryNephrectomyKidney NeoplasmsMLPATumor BurdenSurvival Ratemedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMultiplex ligation-dependent probe amplificationCarbonic Anhydrase IXSurvival rateCarcinoma Renal CellAgedNeoplasm Stagingbusiness.industryCAIXmedicine.disease030104 developmental biologyNeoplasm GradingNeoplasm Recurrence LocalbusinessTranscriptomeFollow-Up StudiesCancer treatment and research communications
researchProduct